ATN 064 Specimen Condition Dataset in Immunogenicity, Safety, Tolerability, and Behavioral Consequences of an HPV-6, -11, -16, -18 Vaccine in HIV-Infected Young Women

Data from Specimen Tracking Form: Blood [CRF 100, question 5]
Study Description
A Phase II, open-label, multi-center study that evaluated the immunogenicity, safety, tolerability, and behavioral impact of an HPV-6, -11, -16, -18 vaccine in HIV-infected young women. The vaccine was administered at the recommended dose and schedule (Day 0, Week 8, and Week 24) with safety assessments after each vaccination and reactive antibody measurements pre- and post-vaccination. Attitudes and behaviors were measured using self-administered questionnaires.
HIV-infected young women between 16 and 23 years of age